How to avoid tumor lysis syndrome when treating CLL patients with venetoclax
Understanding why CLL patients stop responding to treatment, and options for salvage therapies
The iwCLL 2017 meeting
Safety analysis of the BCL-2 inhibitor venetoclax for CLL
What are the benefits of having different chronic lymphocytic leukemia (CLL) treatment options?